Evotec buys Central Glass Germany
Evotec has bought the German manufacturing operations of Japan’s Central Glass for a nominal €1. The deal is subject to customary closing conditions and is expected to close on 1 November. The business will be renamed Evotec Drug Substance (Germany).
The deal brings Evotec a cGMP-certified pharmaceutical manufacturing campus in Halle with about 5,000 m2 of floor space and some 60 employees. According to Evotec, this enhances its strategy of “pursuing integrated discovery and development of new medicines that matter”, notably in precision medicines and rare diseases. The firm added that it intends to “invest meaningfully” to make Halle a centre of excellence for rare disease drug substance manufacturing.